… the use of tocilizumab as the cumulative safety and efficacy with such a drug is larger than for
sarilumab and to consider the use of sarilumab as … use. Our study provides evidence for the …

… use of Sarilumab in patients with severe SARS-CoV-2-related pneumonia. In particular, the
study endpoints were to assess (i) the impact of Sarilumab … rate in patients treated in ICU care…

… combining sarilumab at high doses with corticosteroids early on … In the meantime, it is
reasonable to prioritize the use of … than for sarilumab and to consider the use of sarilumab as an al…

… -IR patients received subcutaneous sarilumab (… , patients could enrol in the open-label,
long-term extension study (EXTEND, NCT011046652), in which all patients received sarilumab …

… This study indicates that sarilumab is safe and effective in a specific subset of patients with
severe hyperinflamed COVID-19 presenting with low percentage of lung consolidation on CT …

Background Elevated proinflammatory cytokines are associated with greater COVID-19 severity.
We aimed to assess safety and efficacy of sarilumab, an interleukin-6 receptor inhibitor, …

… We propose that the early use of sarilumab, in addition to standard therapy, can attenuate
the detrimental host immune response in patients with elevated markers of inflammation by …

… to evaluate if an early therapeutic intervention with sarilumab plus standard of care (… patients
with pneumonia. We also intend to provide data to support the safety of the use of sarilumab …

… ) or IL-6 receptor (sarilumab). One Phase II and six Phase III … a broad efficacy of sarilumab
across all RA patient subtypes, … sarilumab as an alternative therapeutic option in RA patients. …

… with sarilumab … patients with interstitial pneumonia. This study will also provide supportive
evidence to that provided by currently ongoing studies on the efficacy and safety of sarilumab …